Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell and Gene Therapy Market 

5.1. COVID-19 Landscape: Cell and Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cell and Gene Therapy Market, By Therapy Type

8.1. Cell and Gene Therapy Market, by Therapy Type, 2023-2032

8.1.1. Cell Therapy

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Gene Therapy

8.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Cell and Gene Therapy Market, By Therapeutic class

9.1. Cell and Gene Therapy Market, by Therapeutic class, 2023-2032

9.1.1. Cardiovascular Disease

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Cancer

9.1.2.1. Market Revenue and Forecast (2021-2032)

9.1.3. Genetic Disorder

9.1.3.1. Market Revenue and Forecast (2021-2032)

9.1.4. Rare Diseases

9.1.4.1. Market Revenue and Forecast (2021-2032)

9.1.5. Oncology

9.1.5.1. Market Revenue and Forecast (2021-2032)

9.1.6. Oncology

9.1.6.1. Market Revenue and Forecast (2021-2032)

9.1.7. Ophthalmology

9.1.7.1. Market Revenue and Forecast (2021-2032)

9.1.8. Infectious Disease

9.1.8.1. Market Revenue and Forecast (2021-2032)

9.1.9. Neurological Disorders

9.1.9.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Cell and Gene Therapy Market, By Delivery Method 

10.1. Cell and Gene Therapy Market, by Delivery Method, 2023-2032

10.1.1. In Vivo

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Ex vivo

10.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Cell and Gene Therapy Market, By End-Users 

11.1. Cell and Gene Therapy Market, by End-Users, 2023-2032

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast (2021-2032)

11.1.2. Cancer Care Centers

11.1.2.1. Market Revenue and Forecast (2021-2032)

11.1.3. Wound Care Centers

11.1.3.1. Market Revenue and Forecast (2021-2032)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2021-2032)

Chapter 12. Global Cell and Gene Therapy Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.1.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.1.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.1.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.1.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.1.5.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.1.5.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.1.6.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.1.6.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.1.6.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.2.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.2.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.2.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.2.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.2.5.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.2.5.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.2.6.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.2.6.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.2.6.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.2.7.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.2.7.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.2.7.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.2.8.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.2.8.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.2.8.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.3.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.3.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.3.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.3.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.3.5.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.3.5.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.3.6.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.3.6.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.3.6.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.3.7.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.3.7.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.3.7.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.3.8.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.3.8.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.3.8.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.4.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.4.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.4.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.4.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.4.5.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.4.5.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.4.6.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.4.6.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.4.6.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.4.7.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.4.7.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.4.7.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.4.8.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.4.8.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.4.8.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.5.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.5.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.5.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.5.5.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.5.5.4. Market Revenue and Forecast, by End-Users (2021-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Therapy Type (2021-2032)

12.5.6.2. Market Revenue and Forecast, by Therapeutic class (2021-2032)

12.5.6.3. Market Revenue and Forecast, by Delivery Method (2021-2032)

12.5.6.4. Market Revenue and Forecast, by End-Users (2021-2032)

Chapter 13. Company Profiles

13.1. Alnylam Pharmaceuticals Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Amgen Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Biogen Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. CORESTEM Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Dendreon Pharmaceuticals LLC.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Helixmith Co. Ltd.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. JCR Pharmaceuticals Co. Ltd.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Kolon TissueGene Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Novartis AG

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Pfizer Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms